Literature DB >> 22669900

Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population.

Hung Fu Tseng1, Margaret Chi, Ning Smith, Stephen M Marcy, Lina S Sy, Steven J Jacobsen.   

Abstract

BACKGROUND: The benefit of vaccinating immunocompetent patients who have had shingles has not been examined. The study assessed the association between vaccination and the incidence of herpes zoster recurrence among persons with a recent episode of clinically diagnosed herpes zoster.
METHODS: This is a matched cohort study in Kaiser Permanente Southern California. Study populations were immunocompetent elderly individuals ≥ 60 years old with a recent episode of herpes zoster. Incidence of recurrent herpes zoster was compared between the vaccinated and the unvaccinated matched cohorts.
RESULTS: A total of 1036 vaccinated and 5180 unvaccinated members were included. On the basis of clinically confirmed cases, the incidence of recurrent herpes zoster among persons aged <70 years was 0.99 (95% confidence interval [CI], .02-5.54) and 2.20 (95% CI, 1.10-3.93) cases per 1000 person-years in the vaccinated and unvaccinated cohorts, respectively. The adjusted hazard ratio was 0.39 (95% CI, .05-4.45) among persons aged <70 years and 1.05 (95% CI, .30-3.69) among persons aged ≥ 70 years.
CONCLUSIONS: The risk of herpes zoster recurrence following a recent initial episode is fairly low among immunocompetent adults, regardless of vaccination status. Such a low risk suggests that one should evaluate the necessity of immediately vaccinating immunocompetent patients who had a recent herpes zoster episode.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22669900     DOI: 10.1093/infdis/jis334

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Zoster vaccine.

Authors:  Michael R Kolber; Christina Korownyk; Tony Nickonchuk
Journal:  Can Fam Physician       Date:  2013-02       Impact factor: 3.275

2.  Improving adherence to national recommendations for zoster vaccination through simple interventions.

Authors:  Zachary P Elkin; Elisabeth J Cohen; Judith D Goldberg; Xiaochun Li; Eliana Castano; Colleen Gillespie; Ilyse Haberman; Jesse J Jung; Sondra Zabar; Lisa Park; Michael H Perskin
Journal:  Eye Contact Lens       Date:  2014-07       Impact factor: 2.018

3.  Enhanced Potency and Persistence of Immunity to Varicella-Zoster Virus Glycoprotein E in Mice by Addition of a Novel BC02 Compound Adjuvant.

Authors:  Junli Li; Lili Fu; Yang Yang; Guozhi Wang; Aihua Zhao
Journal:  Vaccines (Basel)       Date:  2022-03-29

Review 4.  Clinical practice: Herpes zoster.

Authors:  Jeffrey I Cohen
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

Review 5.  Herpes zoster and postherpetic neuralgia in older adults.

Authors:  Kenneth Schmader
Journal:  Clin Geriatr Med       Date:  2007-08       Impact factor: 3.076

Review 6.  Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-07       Impact factor: 11.431

7.  Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.

Authors:  Emmanuelle Préaud; Mathieu Uhart; Katharina Böhm; Pamela Aidelsburger; Delphine Anger; Florence Bianic; Nathalie Largeron
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Topical and intranasal analgesic therapy in a woman with refractory postherpetic neuralgia.

Authors:  Kenneth C Hohmeier; Lyndsey M Almon
Journal:  Case Rep Med       Date:  2015-04-09

9.  Herpes zoster vaccine in Korea.

Authors:  Won Suk Choi
Journal:  Clin Exp Vaccine Res       Date:  2013-07-03

10.  Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.

Authors:  Bernhard Ultsch; Felix Weidemann; Thomas Reinhold; Anette Siedler; Gérard Krause; Ole Wichmann
Journal:  BMC Health Serv Res       Date:  2013-09-26       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.